Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

715 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical use of rituximab in haematological malignancies.
Avivi I, Robinson S, Goldstone A. Avivi I, et al. Among authors: goldstone a. Br J Cancer. 2003 Oct 20;89(8):1389-94. doi: 10.1038/sj.bjc.6601187. Br J Cancer. 2003. PMID: 14562003 Free PMC article. Review.
T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, White H, Hale G, Waldmann H, Goldstone A, Mackinnon S, Yong K. D'Sa S, et al. Among authors: goldstone a. Br J Haematol. 2003 Oct;123(2):309-22. doi: 10.1046/j.1365-2141.2003.04612.x. Br J Haematol. 2003. PMID: 14531914 Clinical Trial.
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Morris E, et al. Among authors: goldstone a. Blood. 2004 Dec 15;104(13):3865-71. doi: 10.1182/blood-2004-03-1105. Epub 2004 Aug 10. Blood. 2004. PMID: 15304395 Free article.
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Among authors: goldstone a. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Clinical Trial.
Del (9q) AML: clinical and cytological characteristics and prognostic implications.
Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, Wheatley K, Walker H, Chatters S, Harrison C, Boultwood J, Goldstone A, Burnett A. Peniket A, et al. Among authors: goldstone a. Br J Haematol. 2005 Apr;129(2):210-20. doi: 10.1111/j.1365-2141.2005.05445.x. Br J Haematol. 2005. PMID: 15813849
Reply to C. Fozza.
Pettengell R, Schmitz N, Dreger P, Goldstone A. Pettengell R, et al. Among authors: goldstone a. J Clin Oncol. 2013 Oct 20;31(30):3847-8. doi: 10.1200/JCO.2013.51.8951. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062407 No abstract available.
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R. Richardson SE, et al. Among authors: goldstone a. Br J Haematol. 2013 Mar;160(5):640-8. doi: 10.1111/bjh.12197. Epub 2013 Jan 7. Br J Haematol. 2013. PMID: 23293871
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N; Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Kyriakou C, et al. Among authors: goldstone a. J Clin Oncol. 2008 Jan 10;26(2):218-24. doi: 10.1200/JCO.2008.12.6219. J Clin Oncol. 2008. PMID: 18182664
715 results